Gina Mauro

Vice President of Content, OncLive and Cancer Network
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

December 21st 2024

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

December 17th 2024

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.

Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer

December 11th 2024

Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

December 11th 2024

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer

December 11th 2024

Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.

Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR

December 10th 2024

Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma

December 10th 2024

The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.

Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL

December 10th 2024

Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.

Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma

December 9th 2024

Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma

December 8th 2024

Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

December 8th 2024

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

December 8th 2024

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL

December 8th 2024

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

November 22nd 2024

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

November 16th 2024

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Piecing Together the Proper BTK Usage in CLL

November 13th 2024

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

Real-World Experience With CAR T Varies From Trials in DLBCL

November 13th 2024

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

November 13th 2024

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.

Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC

November 8th 2024

Overall survival findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.

CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC

November 8th 2024

Treatment with magrolimab plus docetaxel led to peripheral CD47 saturation in patients with advanced NSCLC, which correlated with improved outcomes.